Lexology September 4, 2024
McGuireWoods Consulting LLC

Click here to listen to the audio.

A revolution in the use of psychedelic drugs to treat mental health issues experienced a setback in early August when the FDA declined to approve MMDA as a treatment for post-traumatic stress disorder.

Host Stephanie Kennan provides important context to the FDA’s decision, which...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, FDA, Govt Agencies, Mental Health, Pharma, Pharma / Biotech, Provider, Trends
Boosting chronic care management with mental health support | Viewpoint
1 in 5 Overdose Deaths in 2022 Had Unrelated Mental Illness
Charlie Health Partners with Cartwheel to Address the Student Mental Health Crisis
Mental Health Medication Trends: Antidepressants Up 21%, Opioids Down 17%
Podcast: Parental Stress New Focus for US Surgeon General

Share This Article